Skip to main content
Top
Published in: Supportive Care in Cancer 7/2010

01-07-2010 | Original Article

Insight in the prediction of chemotherapy-induced nausea

Authors: Joseph A. Roscoe, Gary R. Morrow, Ben Colagiuri, Charles E. Heckler, Bryan D. Pudlo, Lauren Colman, Karen Hoelzer, Andrew Jacobs

Published in: Supportive Care in Cancer | Issue 7/2010

Login to get access

Abstract

Purpose

To identify risk factors for chemotherapy-related nausea.

Methods

We examined risk factors for nausea in 1,696 patients from three multicenter studies conducted from 1998 to 2004. All patients were beginning a chemotherapy regimen containing cisplatin, carboplatin, or doxorubicin. Nausea was assessed on a 1–7 scale four times a day for 4 days by diary.

Results

First, average nausea for breast cancer patients receiving doxorubicin (mean = 2.31) was significantly greater than for other patients receiving doxorubicin (mean = 1.82), patients receiving cisplatin (mean = 1.88), and patients receiving carboplatin (mean = 1.45), Ps < 0.01. Second, mean nausea decreased steadily with age, P < 0.0001. Third, patients rating themselves more susceptible to nausea had significantly more nausea (adjusted mean = 2.51) than patients rating themselves less susceptible (adjusted mean = 1.92) and were 2.8 times more likely to experience severe nausea, Ps < 0.0001. Fourth, expected nausea was a significant predictor of average nausea, P = 0.034, but not severe nausea, P = 0.31. Last, no evidence that gender is a significant predictor of nausea in 299 patients with gender neutral cancers, P = 0.35.

Conclusions

Specific patient characteristics, especially younger age and perceived susceptibility to nausea, can help clinicians in the early identification of patients who are more susceptible to treatment-related nausea.
Literature
1.
go back to reference Klastersky J, Schimpff SC, Senn HJ (1999) Supportive care in cancer, 2nd edn. Marcel Deckker, New York Klastersky J, Schimpff SC, Senn HJ (1999) Supportive care in cancer, 2nd edn. Marcel Deckker, New York
2.
go back to reference Osoba D, Zee B, Warr D, Latreille J, Kaizer L, Pater J (1997) Effect of postchemotherapy nausea and vomiting on health-related quality of life. The quality of life and symptom control committees of the National Cancer Institute of Canada clinical trials group. Support Care Cancer 5:307–313CrossRefPubMed Osoba D, Zee B, Warr D, Latreille J, Kaizer L, Pater J (1997) Effect of postchemotherapy nausea and vomiting on health-related quality of life. The quality of life and symptom control committees of the National Cancer Institute of Canada clinical trials group. Support Care Cancer 5:307–313CrossRefPubMed
3.
go back to reference Morrow GR, Roscoe JA, Hickok JT (1998) Nausea and vomiting. In: Holland JC (ed) Psycho-oncology. Oxford University Press, New York, pp 476–484 Morrow GR, Roscoe JA, Hickok JT (1998) Nausea and vomiting. In: Holland JC (ed) Psycho-oncology. Oxford University Press, New York, pp 476–484
4.
go back to reference Hickok JT, Roscoe JA, Morrow GR, King DK, Atkins JN, Fitch TR (2003) Nausea and emesis remain significant problems of chemotherapy despite prophylaxis with 5-hydroxytryptamine-3 antiemetics: a University of Rochester James P. Wilmot Cancer Center Community Clinical Oncology Program Study of 360 cancer patients treated in the community. Cancer 97:2880–2886CrossRefPubMed Hickok JT, Roscoe JA, Morrow GR, King DK, Atkins JN, Fitch TR (2003) Nausea and emesis remain significant problems of chemotherapy despite prophylaxis with 5-hydroxytryptamine-3 antiemetics: a University of Rochester James P. Wilmot Cancer Center Community Clinical Oncology Program Study of 360 cancer patients treated in the community. Cancer 97:2880–2886CrossRefPubMed
5.
go back to reference (1999) ASHP Therapeutic Guidelines on the Pharmacologic Management of Nausea and Vomiting in Adult and Pediatric Patients Receiving Chemotherapy or Radiation Therapy or Undergoing Surgery. Am J Health Syst Pharm 56:729–764 (1999) ASHP Therapeutic Guidelines on the Pharmacologic Management of Nausea and Vomiting in Adult and Pediatric Patients Receiving Chemotherapy or Radiation Therapy or Undergoing Surgery. Am J Health Syst Pharm 56:729–764
6.
go back to reference Grunberg SM (2004) Chemotherapy-induced nausea and vomiting: prevention, detection, and treatment—how are we doing? The Journal of Supportive Oncology 2:1–10PubMed Grunberg SM (2004) Chemotherapy-induced nausea and vomiting: prevention, detection, and treatment—how are we doing? The Journal of Supportive Oncology 2:1–10PubMed
7.
go back to reference Hesketh PJ, Grunberg SM, Herrstedt J, de WR, Gralla RJ, Carides AD, Taylor A, Evans JK, Horgan KJ (2006) Combined data from two phase III trials of the NK1 antagonist aprepitant plus a 5HT 3 antagonist and a corticosteroid for prevention of chemotherapy-induced nausea and vomiting: effect of gender on treatment response. Support Care Cancer 14:354–360CrossRefPubMed Hesketh PJ, Grunberg SM, Herrstedt J, de WR, Gralla RJ, Carides AD, Taylor A, Evans JK, Horgan KJ (2006) Combined data from two phase III trials of the NK1 antagonist aprepitant plus a 5HT 3 antagonist and a corticosteroid for prevention of chemotherapy-induced nausea and vomiting: effect of gender on treatment response. Support Care Cancer 14:354–360CrossRefPubMed
8.
go back to reference Jordan K, Sippel C, Schmoll HJ (2007) Guidelines for antiemetic treatment of chemotherapy-induced nausea and vomiting: past, present, and future recommendations. Oncologist 12:1143–1150CrossRefPubMed Jordan K, Sippel C, Schmoll HJ (2007) Guidelines for antiemetic treatment of chemotherapy-induced nausea and vomiting: past, present, and future recommendations. Oncologist 12:1143–1150CrossRefPubMed
9.
go back to reference Herrstedt J, Dombernowsky P (2007) Anti-emetic therapy in cancer chemotherapy: current status. Basic & Clinical Pharmacology & Toxicology 101:143–150CrossRef Herrstedt J, Dombernowsky P (2007) Anti-emetic therapy in cancer chemotherapy: current status. Basic & Clinical Pharmacology & Toxicology 101:143–150CrossRef
10.
go back to reference Gralla RJ, Osoba D, Kris MG, Kirkbride P, Hesketh PJ, Chinnery LW, Clark-Snow R, Gill DP, Groshen S, Grunberg S, Koeller JM, Morrow GR, Perez EA, Silber JH, Pfister DG (1999) Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. American Society of Clinical Oncology. J Clin Oncol 17:2971–2994PubMed Gralla RJ, Osoba D, Kris MG, Kirkbride P, Hesketh PJ, Chinnery LW, Clark-Snow R, Gill DP, Groshen S, Grunberg S, Koeller JM, Morrow GR, Perez EA, Silber JH, Pfister DG (1999) Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. American Society of Clinical Oncology. J Clin Oncol 17:2971–2994PubMed
11.
go back to reference Gralla RJ, Itri LM, Pisko SE, Squillante AE, Kelson DP, Braun DW, Bordin LA, Braun TJ (1981) Antiemetic efficacy of high-dose metoclopramide: randomized trials with placebo and prochlorperazine in patients with chemotherapy-induced nausea and vomiting. N Engl J Med 305:905–909PubMed Gralla RJ, Itri LM, Pisko SE, Squillante AE, Kelson DP, Braun DW, Bordin LA, Braun TJ (1981) Antiemetic efficacy of high-dose metoclopramide: randomized trials with placebo and prochlorperazine in patients with chemotherapy-induced nausea and vomiting. N Engl J Med 305:905–909PubMed
13.
go back to reference Hickok JT, Roscoe JA, Morrow GR, Bole CW, Zhao H, Hoelzer KL, Dakhil SR, Moore T, Fitch TR (2005) 5-Hydroxytryptamine-receptor antagonists versus prochlorperazine for control of delayed nausea caused by doxorubicin: a URCC CCOP randomised controlled trial. Lancet Oncol 6:765–772CrossRefPubMed Hickok JT, Roscoe JA, Morrow GR, Bole CW, Zhao H, Hoelzer KL, Dakhil SR, Moore T, Fitch TR (2005) 5-Hydroxytryptamine-receptor antagonists versus prochlorperazine for control of delayed nausea caused by doxorubicin: a URCC CCOP randomised controlled trial. Lancet Oncol 6:765–772CrossRefPubMed
14.
go back to reference Osoba D, Zee B, Pater J, Warr D, Latreille J, Kaizer L (1997) Determinants of postchemotherapy nausea and vomiting in patients with cancer. Quality of life and symptom control committees of the National Cancer Institute of Canada clinical trials group. J Clin Oncol 15:116–123PubMed Osoba D, Zee B, Pater J, Warr D, Latreille J, Kaizer L (1997) Determinants of postchemotherapy nausea and vomiting in patients with cancer. Quality of life and symptom control committees of the National Cancer Institute of Canada clinical trials group. J Clin Oncol 15:116–123PubMed
15.
go back to reference Montgomery GH (2000) Pre-infusion expectations predict post-treatment nausea during repeated adjuvant chemotherapy infusions for breast cancer. Br J Health Psychol 5:105–119CrossRef Montgomery GH (2000) Pre-infusion expectations predict post-treatment nausea during repeated adjuvant chemotherapy infusions for breast cancer. Br J Health Psychol 5:105–119CrossRef
16.
go back to reference Rhodes VA, Watson PM, McDaniel RW, Hanson BM, Johnson MH (1995) Expectation and occurrence of postchemotherapy side effects: nausea and vomiting. Cancer Pract 3:247–253PubMed Rhodes VA, Watson PM, McDaniel RW, Hanson BM, Johnson MH (1995) Expectation and occurrence of postchemotherapy side effects: nausea and vomiting. Cancer Pract 3:247–253PubMed
17.
go back to reference Roscoe JA, Hickok JT, Morrow GR (2000) Patient expectations as predictor of chemotherapy-induced nausea. Annals Behav Med 22:121–126CrossRef Roscoe JA, Hickok JT, Morrow GR (2000) Patient expectations as predictor of chemotherapy-induced nausea. Annals Behav Med 22:121–126CrossRef
18.
go back to reference Roscoe JA, Bushunow P, Morrow GR, Hickok JT, Kuebler PJ, Jacobs A, Banerjee TK (2004) Patient expectation is a strong predictor of severe nausea after chemotherapy: a University of Rochester Community Clinical Oncology Program study of patients with breast carcinoma. Cancer 101:2701–2708CrossRefPubMed Roscoe JA, Bushunow P, Morrow GR, Hickok JT, Kuebler PJ, Jacobs A, Banerjee TK (2004) Patient expectation is a strong predictor of severe nausea after chemotherapy: a University of Rochester Community Clinical Oncology Program study of patients with breast carcinoma. Cancer 101:2701–2708CrossRefPubMed
19.
go back to reference Olver IN, Taylor AE, Whitford HS (2005) Relationships between patients' pre-treatment expectations of toxicities and post chemotherapy experiences. Psychooncology 14:25–33CrossRefPubMed Olver IN, Taylor AE, Whitford HS (2005) Relationships between patients' pre-treatment expectations of toxicities and post chemotherapy experiences. Psychooncology 14:25–33CrossRefPubMed
20.
go back to reference Roscoe JA, Jean-Pierre P, Shelke AR, Kaufman ME, Bole C, Morrow GR (2006) The role of patients' response expectancies in side effect development and control. Curr Probl Cancer 30:40–98CrossRefPubMed Roscoe JA, Jean-Pierre P, Shelke AR, Kaufman ME, Bole C, Morrow GR (2006) The role of patients' response expectancies in side effect development and control. Curr Probl Cancer 30:40–98CrossRefPubMed
21.
go back to reference Colagiuri B, Roscoe JA, Morrow GR, Atkins JN, Giguere JK, Colman LK (2008) How do patient expectancies, quality of life, and postchemotherapy nausea interrelate? Cancer 113:654–661CrossRefPubMed Colagiuri B, Roscoe JA, Morrow GR, Atkins JN, Giguere JK, Colman LK (2008) How do patient expectancies, quality of life, and postchemotherapy nausea interrelate? Cancer 113:654–661CrossRefPubMed
22.
go back to reference Shelke AR, Roscoe JA, Morrow GR, Colman LK, Banerjee TK, Kirshner JJ (2008) Effect of a nausea expectancy manipulation on chemotherapy-induced nausea: a University of Rochester Cancer Center Community Clinical Oncology Program study. J Pain Symptom Manage 35:381–387CrossRefPubMed Shelke AR, Roscoe JA, Morrow GR, Colman LK, Banerjee TK, Kirshner JJ (2008) Effect of a nausea expectancy manipulation on chemotherapy-induced nausea: a University of Rochester Cancer Center Community Clinical Oncology Program study. J Pain Symptom Manage 35:381–387CrossRefPubMed
23.
go back to reference Roscoe JA, Morrow GR, Hickok JT, Bushunow PW, Pierce HI, Flynn PJ, Kirshner JJ, Moore DF Jr, Atkins JN (2003) The efficacy of acupressure and acustimulation wrist bands for the relief of chemotherapy-induced nausea and vomiting: a URCC CCOP multicenter study. J Pain Symptom Manage 26:731–742CrossRefPubMed Roscoe JA, Morrow GR, Hickok JT, Bushunow PW, Pierce HI, Flynn PJ, Kirshner JJ, Moore DF Jr, Atkins JN (2003) The efficacy of acupressure and acustimulation wrist bands for the relief of chemotherapy-induced nausea and vomiting: a URCC CCOP multicenter study. J Pain Symptom Manage 26:731–742CrossRefPubMed
24.
go back to reference Burish TG, Carey MP, Krozely MG, Greco FA (1987) Conditioned side effects induced by cancer chemotherapy: prevention through behavioral treatment. J Consult Clin Psychol 55:42–48CrossRefPubMed Burish TG, Carey MP, Krozely MG, Greco FA (1987) Conditioned side effects induced by cancer chemotherapy: prevention through behavioral treatment. J Consult Clin Psychol 55:42–48CrossRefPubMed
25.
go back to reference Carey MP, Burish TG (1988) Etiology and treatment of the psychological side effects associated with cancer chemotherapy: a critical review and discussion. Psychol Bull 104:307–325CrossRefPubMed Carey MP, Burish TG (1988) Etiology and treatment of the psychological side effects associated with cancer chemotherapy: a critical review and discussion. Psychol Bull 104:307–325CrossRefPubMed
26.
go back to reference (2004) Chemotherapy-induced nausea and vomiting (CINV): prevention, detection, and treatment—how are we doing? ONS News 19:61–62 (2004) Chemotherapy-induced nausea and vomiting (CINV): prevention, detection, and treatment—how are we doing? ONS News 19:61–62
27.
go back to reference Schwartzberg LS (2007) Chemotherapy-induced nausea and vomiting: clinician and patient perspectives. The Journal of Supportive Oncology 5:5–12PubMed Schwartzberg LS (2007) Chemotherapy-induced nausea and vomiting: clinician and patient perspectives. The Journal of Supportive Oncology 5:5–12PubMed
28.
go back to reference Barsky AJ, Saintfort R, Rogers MP, Borus JF (2002) Nonspecific medication side effects and the nocebo phenomenon. JAMA 287:622–627CrossRefPubMed Barsky AJ, Saintfort R, Rogers MP, Borus JF (2002) Nonspecific medication side effects and the nocebo phenomenon. JAMA 287:622–627CrossRefPubMed
Metadata
Title
Insight in the prediction of chemotherapy-induced nausea
Authors
Joseph A. Roscoe
Gary R. Morrow
Ben Colagiuri
Charles E. Heckler
Bryan D. Pudlo
Lauren Colman
Karen Hoelzer
Andrew Jacobs
Publication date
01-07-2010
Publisher
Springer-Verlag
Published in
Supportive Care in Cancer / Issue 7/2010
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-009-0723-2

Other articles of this Issue 7/2010

Supportive Care in Cancer 7/2010 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine